Loading...
•
Jun 30, 2020
Guardant Health Q2 2020 Earnings Report
Reported a 23% revenue increase compared to the prior year period.
Key Takeaways
Guardant Health reported a 23% increase in revenue for the second quarter of 2020, driven by growth in both precision oncology and development services. The company's cash position was strengthened by a public offering, ending the quarter with $1.1 billion in cash, cash equivalents and marketable securities.
Revenue of $66.3 million for the second quarter of 2020, an increase of 23% over the corresponding period of 2019
Precision oncology revenue of $51.0 million, an increase of 21% over the corresponding period of 2019
Reported 13,694 tests to clinical customers and 2,805 tests to biopharmaceutical customers in the second quarter of 2020, representing an increase of 15% and a decrease of 47%, respectively, over the second quarter of 2019
Ended the second quarter with $1.1 billion cash, cash equivalents and marketable securities
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.